The Company will develop and produce premixes for human nutrition applications

Kullu, 7th September 2023 :

Fermenta’s plant, dedicated to the manufacture of customized premixes, possesses FSSAI license and can cater to both powder and liquid premix requirements. The premix plant is backed by technical expertise from Fermenta’s formulation development lab in Thane, Maharashtra, and possesses all necessary infrastructure to ensure uniformity and consistency of the products. Leveraging its experience and strengths in Vitamin D, Fermenta will source its ingredients for premixes in a sustainable and reliable manner.

Mr Prashant Nagre, Managing Director of Fermenta, commented on the occasion, “At Fermenta, we recognize the global challenge of micronutrient deficiency, and we are fully committed to addressing it through our products. We firmly believe in our ability to make a significant impact on improving human nutrition and well-being globally. We have established ourselves as a trusted partner for Vitamin D customers globally and now bring the same commitment to delivering high-quality premixes.”

The inauguration of the premix facility marks a milestone in Fermenta’s goals to add offerings to its emerging portfolio of nutrition.

About Fermenta Biotech Limited (FBL):

Founded in 1951, Fermenta Biotech Limited (FBL) possesses a growing portfolio of nutrition including Customized Premixes, Fortified Rice Kernel (FRK) and other nutritional ingredients. Apart from its nutrition portfolio, FBL is the only manufacturer of Vitamin D3 in India and a leading global player. It caters to over 350 customers across 60 countries with a worldwide distribution network for a variety of applications such as pharmaceuticals, dietary and nutritional supplements, food, animal nutrition and rodenticides. FBL's manufacturing facilities in Kullu and Dahej are certificated by global accreditations and its world class R&D centre is located at Thane. FBL also possesses expertise in integrated biotechnology such as enzymes for antibiotic synthesis, other niche APIs and environmental solutions.

For more information about the Company and its businesses, please visit our website www.fermentabiotech.com

Safe Harbor :

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

This is a press release received from Fermenta Biotech Limited, any views, opinions, statements, or information contained in this press release are solely those of Fermenta Biotech Limited and do not reflect the views or opinions of Medicircle.